UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

Clinical cancer research, 2022-04, Vol.28 (8), p.1572-1585

2022

Volltextzugriff (PDF)

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

Haematologica (Roma), 2021-02, Vol.106 (2), p.585-588

2021

Volltextzugriff (PDF)

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001607

2020

Volltextzugriff (PDF)

Double Umbilical Cord Blood Transplantation in High‐Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

HemaSphere, 2019-10, Vol.3 (5), p.1-4

2019

Volltextzugriff (PDF)

CD45RA + CCR7 - CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Journal for immunotherapy of cancer, 2019-06, Vol.7 (1), p.149-13, Article 149

2019

Volltextzugriff (PDF)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Frontiers in immunology, 2018-09, Vol.9, p.2034-2034

2018

Volltextzugriff (PDF)

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation

Bone marrow transplantation (Basingstoke), 2018-06, Vol.53 (6), p.673-682

2018

Volltextzugriff (PDF)

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

Clinical cancer research, 2017-10, Vol.23 (20), p.6012-6020

2017

Volltextzugriff (PDF)

Graft predominance after double umbilical cord blood transplantation: a review

Stem cell investigation, 2017-05, Vol.4 (6), p.47-47

2017

Volltextzugriff (PDF)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

Frontiers in immunology, 2016-12, Vol.7, p.648-648

2016

Volltextzugriff (PDF)

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Blood, 2016-10, Vol.128 (17), p.2165-2174

2016

Volltextzugriff (PDF)

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells

Clinical immunology (Orlando, Fla.), 2016-08, Vol.169, p.107-113

2016

Volltextzugriff (PDF)

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

Biochemical Society transactions, 2016-06, Vol.44 (3), p.951-959

2016

Volltextzugriff (PDF)

Adoptive T-cell therapy: a need for standard immune monitoring

Immunotherapy, 2015-05, Vol.7 (5), p.513-533

2015

Volltextzugriff (PDF)

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

Human gene therapy. Part B. Methods, 2014-12, Vol.25 (6), p.345-357

2014

Volltextzugriff (PDF)

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Clinical cancer research, 2014-09, Vol.20 (18), p.4776-4783

2014

Volltextzugriff (PDF)

Genetically modified T lymphocytes: more than just direct effectors

Immunotherapy, 2013-07, Vol.5 (7), p.691-694

2013

Volltextzugriff (PDF)

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Cytotherapy (Oxford, England), 2013-05, Vol.15 (5), p.620-626

2013

Volltextzugriff (PDF)

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Molecular therapy, 2013-04, Vol.21 (4), p.904-912

2013

Volltextzugriff (PDF)

Inflammation and Fatigue Dimensions in Advanced Cancer Patients and Cancer Survivors: An Explorative Study

Cancer, 2012-12, Vol.118 (23), p.6005-6011

2012

Volltextzugriff (PDF)

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Cancer, 2012-12, Vol.118 (23), p.6005-6011

2012

Volltextzugriff (PDF)

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies

Neuro-oncology (Charlottesville, Va.), 2012-07, Vol.14 (7), p.841-848

2012

Volltextzugriff (PDF)

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

Blood, 2011-01, Vol.117 (1), p.72-82

2011

Volltextzugriff (PDF)

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

Clinical cancer research, 2010-12, Vol.16 (23), p.5852-5861

2010

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(49)
Dissertationen
(1)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Double Umbilical Cord Blood Transplantation in High‐Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

CD45RA + CCR7 - CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

Graft predominance after double umbilical cord blood transplantation: a review

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

Adoptive T-cell therapy: a need for standard immune monitoring

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Genetically modified T lymphocytes: more than just direct effectors

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Inflammation and Fatigue Dimensions in Advanced Cancer Patients and Cancer Survivors: An Explorative Study

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

Suchergebnisse filtern